NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, is expanding its support throughout the maternal health journey with the addition of doula services. Currently pregnancy, childbirth, and perinatal conditions represent one of the largest shares of employer health spend in the U.S. The addition of in-person and virtual doula services to Progyny's comprehensive maternal offerings will further its ability to provide equitable, high-quality care that can improve outcomes across a diverse member population. As the company formally rolls out its doula offering, Progyny is adding Pacify, a leading provider of maternity care

NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the launch of its Parent and Child Well-being offering, designed to support and alleviate stress for working parents and caregivers. This offering extends Progyny's ability to provide continuous support for parents from preconception through early childhood development, ultimately enhancing job satisfaction and retention. Nearly 40% of the U.S. workforce consists of parents with children under the age of 18, and 48% of those parents say most days their stress is overwhelming. As employers recognize the need to meaningfully support their

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced it expects to participate in several upcoming investor conferences. Progyny executives will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on Monday, March 10, 2025, at 11:20 a.m. Eastern Time. The executives will then be participating in meetings at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on Tuesday, March 11, 2025. Pete Anevski, Chief Executive Officer, will also participate in a virtual fireside chat at the KeyBanc Capital Markets Healthcar

Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",

Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.41

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025. Debra Morris currently serves as President of AccessHope, a company changing the way leading-edge cancer expertise is delivered. Previously she served as EVP and CFO of Apria Healthcare where she demonstrated her ability to navigate complex industry challenges, drive operational excellence, and deliver value to stakeholders. With her extensive board service and proven leadership in handling periods o

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced that the Company is participating in the 43rd Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2024. In its November earnings call, the Company stated that its guidance ranges for the quarterly period ending December 31, 2024 ("the fourth quarter") assumed member activity would be flat to down as compared to the quarterly period ending September 30, 2024. While there were early indicators of improved pa

BLOOMFIELD, Conn., Jan. 13, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE:CI), today announced a new offering in collaboration with Progyny, Inc (NASDAQ:PGNY) that makes best-in-class fertility and family-building services accessible and equitable for more employers. This new and comprehensive benefit will enable employers to offer expanded coverage throughout the entire fertility journey, from pre-conception planning to postpartum care, along with coverage options for family-building services such as surrogacy and adoption. Histo

Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

Canaccord Genuity downgraded Progyny from Buy to Hold and set a new price target of $24.00 from $37.00 previously

BTIG Research downgraded Progyny from Buy to Neutral

Leerink Partners downgraded Progyny from Outperform to Market Perform and set a new price target of $25.00 from $31.00 previously

JMP Securities initiated coverage of Progyny with a rating of Mkt Outperform and set a new price target of $36.00

KeyBanc Capital Markets downgraded Progyny from Overweight to Sector Weight

Leerink Partners initiated coverage of Progyny with a rating of Outperform and set a new price target of $49.00

Barclays initiated coverage of Progyny with a rating of Overweight and set a new price target of $48.00

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

3 - Progyny, Inc. (0001551306) (Issuer)

4 - Progyny, Inc. (0001551306) (Issuer)

S-8 - Progyny, Inc. (0001551306) (Filer)

10-K - Progyny, Inc. (0001551306) (Filer)

8-K/A - Progyny, Inc. (0001551306) (Filer)

8-K - Progyny, Inc. (0001551306) (Filer)

8-K - Progyny, Inc. (0001551306) (Filer)

8-K - Progyny, Inc. (0001551306) (Filer)

144 - Progyny, Inc. (0001551306) (Subject)

10-Q - Progyny, Inc. (0001551306) (Filer)

8-K - Progyny, Inc. (0001551306) (Filer)

8-K - Progyny, Inc. (0001551306) (Filer)

Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025. Debra Morris currently serves as President of AccessHope, a company changing the way leading-edge cancer expertise is delivered. Previously she served as EVP and CFO of Apria Healthcare where she demonstrated her ability to navigate complex industry challenges, drive operational excellence, and deliver value to stakeholders. With her extensive board service and proven leadership in handling periods o

NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny's guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care. Progyny's global benefits solution supports multinational employers and their employee populations in over 100 countries. Progyny's services allow employers the flexibility to offer fertility and family building benefits that co

NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced two newly created roles with the appointment of Katie Higgins as Chief Commercial Officer and Steven Leist as Chief Technology Officer. "We are excited to expand our executive team and welcome Katie and Steven to Progyny. Their expertise will further advance our growth and momentum in the fertility, family building, and women's health benefits space," said Pete Anevski, Progyny's CEO. With over 25 years of healthcare experience, Katie Higgins will be overseeing the teams that drive revenue, business growth, and client succes

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of Janet Choi, M.D., as the company's Chief Medical Officer. Dr. Choi brings more than 20 years of experience in the field as a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology. In her new role, she will lead clinical strategy working closely with the company's executive team and medical advisory board to ensure Progyny offers the highest quality and most effective family building and women's health benefits possible. "I am thrilled to offici

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of a new member to its board of directors, effective August 30, 2022. Joining the board is Lloyd Dean, Chief Executive Emeritus and Founding Executive of CommonSpirit Health. "I am excited to welcome Lloyd to the Board and believe the value he brings from his experience on expanding access to healthcare will be an asset as we explore how we can further our reach when it comes to infertility and family building," said Pete Anevski, Chief Executive Officer of Progyny. "He brings compl

LOS ANGELES--(BUSINESS WIRE)--In line with its mission to create a reliable, elevated and technology-driven experience, Alchemy 43, which is currently raising a $10M Series B, announced today the hiring of Kimberly Joerger as the company’s new Chief Operating Officer, and Dr. Sarmela Sunder as its new Los Angeles Medical Director. Both will report directly to Nicci Levy, Founder and CEO of the revolutionary medical aesthetics brand that specializes in enhancement and prevention. Additionally, Alchemy 43 has added industry titan, Gina Bartasi to its Board of Directors. With a career that spans across both tech and retail sectors, Joerger comes most recently from Stitch Fix. During h

Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.41

Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest Services in Maternity and/or Menopause Programs in 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended September 30, 2024 ("the third quarter of 2024") as compared to the three-month period ended September 30, 2023 ("the third quarter of 2023" or "the prior year period"). "The utilization r

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended September 30, 2024 after the close of the market on Tuesday, November 12, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and usin

Achieves Record Quarterly Adjusted EBITDA, Strong Cash Flow Conversion RateBoard Authorizes Repurchase of $100 Million of Common Stock NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended June 30, 2024 ("the second quarter of 2024") as compared to the three-month period ended June 30, 2023 ("the second quarter of 2023" or "the prior year period"). "The rate of utilization in the second quarter was consistent with our expectations, indicating that the demand for treatment remains both healt

NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended June 30, 2024 after the close of the market on Tuesday, August 6, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the sa

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended March 31, 2024 ("the first quarter of 2024") as compared to the three-month period ended March 31, 2023 ("the first quarter of 2023" or "the prior year period"). "Utilization through the end of February was consistent with the record engagement we saw a year ago. However, March was modestly below our expectations, coinciding with the national conversations concerning fertility treatments and access to maternal healthcare following the Alab

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended March 31, 2024 after the close of the market on Thursday, May 9, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the sa

Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% GrowthAchieves 49% Growth in Adjusted EBITDA to Record $187.1 MillionIssues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the full year", respectively) as compared to the three- and twelve-month periods December 31, 2022 ("the fourth quarter of 2022" and "the prior year perio

NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2023 after the close of the market on Tuesday, February 27, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)

SC 13G/A - Progyny, Inc. (0001551306) (Subject)